Scholarlink

Purpose of Review <p>The domain of cardiac pacing has seen continuous advancements to enhance therapy safety, efficacy, and reliability. This review aims to explore the development of leadless pacemakers as an alternative to traditional transvenous pacing, which often involves complications such as infections, lead fractures, pneumothorax, and valvular issues.</p> Recent Findings <p>Traditional pacing relies on transvenous leads placed in the venous system, which exposes patients to potential complications. In response, leadless pacemakers have been developed, offering a promising solution to these challenges. The Medtronic Micra transcatheter pacing system received FDA approval in April 2016, followed by the Abbott Aveir pacemaker in April 2022. These devices represent a growing field of leadless technology, with several other pacemakers currently in development. Despite their growing use, there is limited guidance on how to select the most suitable candidates for leadless pacemaker therapy.</p> Summary <p>Leadless pacemakers offer significant advantages, including a reduced risk of infection and the ability to manage patients with limited vascular access. As this technology continues to evolve, it is expected to offer a safer, more reliable alternative for patients requiring cardiac pacing.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Advancement in Leadless Pacemaker Technology and its Clinical Aspect

  • 期刊论文

  • 发表日期：

    2025年7月4日

查看全文
  • Taimoor Imran,
  • Samina Abdul Samad,
  • Sataish Fatima,
  • Haider Imran,
  • Luqman Hakeem,
  • Aaliya Mohiuddin,
  • Rohith Arun Jadhav,
  • Muhammad Ali Muzammil

摘要

Purpose of Review

The domain of cardiac pacing has seen continuous advancements to enhance therapy safety, efficacy, and reliability. This review aims to explore the development of leadless pacemakers as an alternative to traditional transvenous pacing, which often involves complications such as infections, lead fractures, pneumothorax, and valvular issues.

Recent Findings

Traditional pacing relies on transvenous leads placed in the venous system, which exposes patients to potential complications. In response, leadless pacemakers have been developed, offering a promising solution to these challenges. The Medtronic Micra transcatheter pacing system received FDA approval in April 2016, followed by the Abbott Aveir pacemaker in April 2022. These devices represent a growing field of leadless technology, with several other pacemakers currently in development. Despite their growing use, there is limited guidance on how to select the most suitable candidates for leadless pacemaker therapy.

Summary

Leadless pacemakers offer significant advantages, including a reduced risk of infection and the ability to manage patients with limited vascular access. As this technology continues to evolve, it is expected to offer a safer, more reliable alternative for patients requiring cardiac pacing.